CA1285223C - Detection of vascular disease - Google Patents
Detection of vascular diseaseInfo
- Publication number
- CA1285223C CA1285223C CA000550932A CA550932A CA1285223C CA 1285223 C CA1285223 C CA 1285223C CA 000550932 A CA000550932 A CA 000550932A CA 550932 A CA550932 A CA 550932A CA 1285223 C CA1285223 C CA 1285223C
- Authority
- CA
- Canada
- Prior art keywords
- conjugate
- antibody
- fragment
- reagent
- insoluble
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 208000019553 vascular disease Diseases 0.000 title claims abstract description 13
- 238000001514 detection method Methods 0.000 title claims abstract description 11
- 239000003153 chemical reaction reagent Substances 0.000 claims abstract description 25
- 238000002372 labelling Methods 0.000 claims abstract description 16
- 230000002792 vascular Effects 0.000 claims abstract description 9
- 201000001320 Atherosclerosis Diseases 0.000 claims abstract description 7
- 238000000034 method Methods 0.000 claims description 30
- 239000012634 fragment Substances 0.000 claims description 25
- 229920002549 elastin Polymers 0.000 claims description 15
- 102000016942 Elastin Human genes 0.000 claims description 13
- 108010014258 Elastin Proteins 0.000 claims description 13
- 230000005855 radiation Effects 0.000 claims description 8
- 102000005598 Chondroitin Sulfate Proteoglycans Human genes 0.000 claims description 7
- 108010059480 Chondroitin Sulfate Proteoglycans Proteins 0.000 claims description 7
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 claims description 4
- 239000002872 contrast media Substances 0.000 claims description 4
- 230000005291 magnetic effect Effects 0.000 claims description 4
- 201000010099 disease Diseases 0.000 claims description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 3
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims description 2
- 229910052688 Gadolinium Inorganic materials 0.000 claims description 2
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 claims description 2
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 claims description 2
- 229910017052 cobalt Inorganic materials 0.000 claims description 2
- 239000010941 cobalt Substances 0.000 claims description 2
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 claims description 2
- 229910052802 copper Inorganic materials 0.000 claims description 2
- 239000010949 copper Substances 0.000 claims description 2
- UIWYJDYFSGRHKR-UHFFFAOYSA-N gadolinium atom Chemical compound [Gd] UIWYJDYFSGRHKR-UHFFFAOYSA-N 0.000 claims description 2
- 229910052759 nickel Inorganic materials 0.000 claims description 2
- 150000004032 porphyrins Chemical class 0.000 claims 2
- 238000012307 MRI technique Methods 0.000 claims 1
- 230000005856 abnormality Effects 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 150000002696 manganese Chemical class 0.000 claims 1
- 230000003902 lesion Effects 0.000 abstract description 16
- 230000003143 atherosclerotic effect Effects 0.000 abstract description 9
- 102000007330 LDL Lipoproteins Human genes 0.000 description 7
- 108010007622 LDL Lipoproteins Proteins 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 7
- 241000283973 Oryctolagus cuniculus Species 0.000 description 7
- 210000004408 hybridoma Anatomy 0.000 description 6
- 102000016611 Proteoglycans Human genes 0.000 description 5
- 108010067787 Proteoglycans Proteins 0.000 description 5
- 210000001367 artery Anatomy 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 102000008186 Collagen Human genes 0.000 description 4
- 108010035532 Collagen Proteins 0.000 description 4
- 102000004895 Lipoproteins Human genes 0.000 description 4
- 108090001030 Lipoproteins Proteins 0.000 description 4
- 239000002671 adjuvant Substances 0.000 description 4
- 210000000709 aorta Anatomy 0.000 description 4
- 229920001436 collagen Polymers 0.000 description 4
- 208000037260 Atherosclerotic Plaque Diseases 0.000 description 3
- 230000000890 antigenic effect Effects 0.000 description 3
- 210000000702 aorta abdominal Anatomy 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 210000004754 hybrid cell Anatomy 0.000 description 3
- 238000003384 imaging method Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 210000004698 lymphocyte Anatomy 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 3
- FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 206010003445 Ascites Diseases 0.000 description 2
- 229920001287 Chondroitin sulfate Polymers 0.000 description 2
- 101000851054 Homo sapiens Elastin Proteins 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- QPCDCPDFJACHGM-UHFFFAOYSA-N N,N-bis{2-[bis(carboxymethyl)amino]ethyl}glycine Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(=O)O)CCN(CC(O)=O)CC(O)=O QPCDCPDFJACHGM-UHFFFAOYSA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 description 2
- 229920002684 Sepharose Polymers 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 230000035508 accumulation Effects 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- -1 cyclic anhydride Chemical class 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 102000054289 human ELN Human genes 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 238000002595 magnetic resonance imaging Methods 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 201000000050 myeloid neoplasm Diseases 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 229960003330 pentetic acid Drugs 0.000 description 2
- XOJVVFBFDXDTEG-UHFFFAOYSA-N pristane Chemical compound CC(C)CCCC(C)CCCC(C)CCCC(C)C XOJVVFBFDXDTEG-UHFFFAOYSA-N 0.000 description 2
- 210000004989 spleen cell Anatomy 0.000 description 2
- 230000008733 trauma Effects 0.000 description 2
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 description 1
- 200000000007 Arterial disease Diseases 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 206010003211 Arteriosclerosis coronary artery Diseases 0.000 description 1
- 229920002567 Chondroitin Polymers 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000006354 HLA-DR Antigens Human genes 0.000 description 1
- 108010058597 HLA-DR Antigens Proteins 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- 208000032382 Ischaemic stroke Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 241000276498 Pollachius virens Species 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 208000024248 Vascular System injury Diseases 0.000 description 1
- 208000012339 Vascular injury Diseases 0.000 description 1
- 206010053648 Vascular occlusion Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- 238000002583 angiography Methods 0.000 description 1
- 238000002399 angioplasty Methods 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 230000036523 atherogenesis Effects 0.000 description 1
- 238000011888 autopsy Methods 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 210000001715 carotid artery Anatomy 0.000 description 1
- 230000007910 cell fusion Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000009920 chelation Effects 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- DLGJWSVWTWEWBJ-HGGSSLSASA-N chondroitin Chemical compound CC(O)=N[C@@H]1[C@H](O)O[C@H](CO)[C@H](O)[C@@H]1OC1[C@H](O)[C@H](O)C=C(C(O)=O)O1 DLGJWSVWTWEWBJ-HGGSSLSASA-N 0.000 description 1
- KXKPYJOVDUMHGS-OSRGNVMNSA-N chondroitin sulfate Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](OS(O)(=O)=O)[C@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](C(O)=O)O1 KXKPYJOVDUMHGS-OSRGNVMNSA-N 0.000 description 1
- 229940059329 chondroitin sulfate Drugs 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 208000026758 coronary atherosclerosis Diseases 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000005292 diamagnetic effect Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 210000000497 foam cell Anatomy 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 230000005251 gamma ray Effects 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000007574 infarction Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 208000023589 ischemic disease Diseases 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 229910052748 manganese Inorganic materials 0.000 description 1
- 239000011572 manganese Substances 0.000 description 1
- 238000005374 membrane filtration Methods 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 210000003200 peritoneal cavity Anatomy 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000037452 priming Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 238000000163 radioactive labelling Methods 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 235000009518 sodium iodide Nutrition 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 229940043517 specific immunoglobulins Drugs 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 238000001931 thermography Methods 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000036269 ulceration Effects 0.000 description 1
- 208000021331 vascular occlusion disease Diseases 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
- A61K49/10—Organic compounds
- A61K49/14—Peptides, e.g. proteins
- A61K49/16—Antibodies; Immunoglobulins; Fragments thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1018—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2123/00—Preparations for testing in vivo
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Physics & Mathematics (AREA)
- Pharmacology & Pharmacy (AREA)
- Optics & Photonics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Radiology & Medical Imaging (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Abstract of the Disclosure Vascular diseases including asymptomatic atherosclerosis can be diagnosed by administering a conjugate diagnostic reagent to a patient and then detecting the location and concentration of the conjugate reagent within the patient's vascular system. The conjugate reagents have a target-seeking, biologically active molecule as one component and a labeling means capable of extracorporeal detection as the other component. The biologically active molecules (BAMs) are chosen to have affinity for structural elements of the arterial wall which are either not present in the normal wall but are found in atherosclerotic or arteritic lesions, or which are not available to the blood-borne reagent within normal arterial walls, but are exposed to the reagent in atherosclerotic or arteritic lesions.
Description
~285223 DETECTION OF VASCULAR DISEASE
Backqround The u.S. Government has rights in this invention pursuant to NIH Grant No. ROlHL32975.
The technical field of this invention concerns methods and means for detecting vascular diseases, such as atherosclerotic lesions, and in particular, methods and means employing labeled, target-seeking, biologically active molecules to 10 detect abnormal arterial structures or compositions.
Atherosclerosis is a disease which causes the thickening and hardening of the arteries, particularly the larger artery walls. It is characterized by lesions of raised fibrous plaque 15 which form within the arterial lumen. The p aques are most prevalent in the abdominal aorta, coronary arteries or carotid arteries and they increase progressively with age. They commonly present dome-shaped, opaque, glistening surfaces which bulge 20 into the lumen. A lesion typically will consist of a central core of lipid and necrotic cell debris, capped by a collagen fibromuscular layer.
Complicated lesions will also include calcified deposits and e~hibit various degrees of necrosis, 25 thrombosis and ulceration.
The deformities of the arterial lumen presented by the plaque and associated deposits result in occluded blood flow, and ultimately ischemic heart disease, stroke, or diseases of other 30 organs, if untreated. At present, coronary atherosclerosis is still the leading cause of death in the United States, claiming ths lives of over a half million Americans annually, roughly twice as many as are killed by cancer.
Unfortunately, the early stages of atherosclerosis and related vascular diseases are most often clinically silent. Since lifestyle changes, drug therapy and other means exist for delayinq or reducing vascular occlusion or the 10 stresses on various body organs which result from atherosclerotic lesions, the early detection of atheromatous plaque in the vascular system would be of considerable value in permitting preventive intervention at a time when it can be most effective.
Arteriography, the conventional approach to assessing vascular disease, involves catheterization and the injection of radioopaque substances into the bloodstream in order to image obstructions in the arteries. This procedure involves significant 20 morbidity, in that infection, perforation of the artery, arrhythmia, stroke, infarction and even death can occur. Because of the risks involved, arteriograms typically are reserved for individuals with advanced or acute atherosclerotic disease.
1 A variety of less invasive techniques for the diagnosis of vascular diseases have been proposed. These techniques include plethysmography, thermography and ultrasonic scanning. For a further review of these techniques, see an article by the present inventor and a colleague, Lees and Myers, "Non-Invasive Diagnosis of Arterial Disease", Vol. 27 Annals of Internal Medicine, pp.
475-509 (1982).
Another non-invasive approach to the diagnosis of vascular disease which has been proposed by the present inventor involves the labeling of low density lipoproteins (LDLs) with radioisotopes and the administration of such labeled LDLs to a patient. 8ecause atherosclerotic plaques tend to take up lipoproteins from the blood circulating in the arteries, the labeled LDLs can be imaged with a gamma camera or other radiation detector to provide information on the location and extent of plaque in the vascular system.
For details on this approach, see U.S. Patent No. 4,647,445 entitled "Radiolabelled Lipoproteins and Methods for Making Same" to Robert S. Lees which issued March 3, 1987.
One disadvantage to the use of labeled LDL's is that the patient's own blood typically is the most appropriate source of lipoproteins, and this entails a two or three day delay between the beginning and the end of the study. Often, such a time period is ,::
~ ......
...... .
not available for sick patients. Furthermore, labeled LDLs image acute, rapidly qrowing atherosclerosic lesions, as reported by the present inventor and colleagues, ~ees et al., Journal of Nuclear Mçdi~ag~, Vol. 24, pp. 154-156, 1983.
The need exists to localize less rapidly yrowing artherosclerosic lesions which may not take up LDLs rapidly enough to be imaged. Consequently, there e~ists a need for better non-invasive techniques and reagents capable of detecting vascular diseases, locating arterial lesions and quantifying the e~tent of vascular injury.
;, i28~i223 Summary of the Invention Vascular diseases, including asymptomatic atherosclerosis, can be diagnosed by administering a conjugate diagnostic reagent to a patient and then 5 detecting the location and concentration of the conjugate reagent within the patient's vascular system. The conjugate reagents have a target-seeking, biologically active molecule as one component and a labeling means capable of 10 extracorporeal detection as the other component. The biologically active molecules (BAMs) are chosen to have affinity for structural elements of the arterial wall which are either not present in the normal wall but are found in atherosclerotic lesions, or which 15 are not available to the blood-borne reagent within normal arterial walls, but are e~posed to the reagent in atherosclerotic lesions.
In particular, the invention encompasses conjugates of radionuclides with various antibodies 20 or fragments thereof which have affinity for certain arterial wall components which are exposed to the blood in atherosclerosis. Two conjugated reagents having particularly useful BAMs are disclosed. The BAMs have high affinity for elastin and chondroitin 25 sulfate proteoglycans ~CSPG), respectively. The conjugates of the present invention can be administered individually or in conjunction with each other.
Suitable radionuclides include Co-57, Cu-67, Ga-67, Ga-68, Ru-97, Tc-99m, In-lll, In-113m, I-123, I-125, I-131, Hg-197, Au-198, and Pb-203. The BAMs and radionuclides can be linked by direct labeling 5 (e.g., by acidic buffered reactions or oxidative procedures) or by ligand exchange or chelation. The radionuclides are preferably imaged with a radiation detection means capable of detecting gamma radiation, such as a gamma camera or the like.
Typically, radiation imaging cameras employ a conversion medium (wherein the high energy gamma ray is absorbed, displacing an electron which emits a photon upon its return to the orbital state), photoelectric detectors arranged in a spatial 15 detection chamber (to determine the position of the emitted photons), and circuitry to analyze the photons detected in the chamber and produce an image.
The invention can also be practiced with non-radioactive labeling means, such as magnetic 20 contrast agents capable of detection in magnetic resonance imaging (MRI) systems. In such systems, a strong magnetic field is used to align the nuclear spin vectors of the atoms in a patient's body. The field is then disturbed and an image of the patient 25 is read as the nuclei return to their equilibrium alignments. In the present invention, target-seeking ~AMs can be linked to diamagnetic contrast agents, such as gadolinium, cobalt, nickel, manganese or copper compleses, to form conjugate diagnostic 30 reagents that are imaged extracorporeally with an MRI
system.
~352Z3 The invention will next be described in connection with certain preferred embodiments;
however, it should be clear that various changes, additions and subtractions can be made without 5 departing from the spirit or scope of the invention.
For esample, monoclonal antibodies (or fragments thereof) as well as polyclonal antibodies (or fragments) can be employed as target-seeking, biologically active molecules. Additionally, human 10 antibodies (i.e., obtained from human-human or human-animal hybridomas) can be used as well as animal antibodies.
Moreover, it should be clear that various antigenic determinants can be used to identify 15 atherosclerotic plaque. Although the embodiments that follow describe two such determinants in detail, elastin and chondroitin sulfate proteogylcans (CSPG), it should be clear that other determinants can also be used as targets against which BAMs can be raised 20 and used in conjugate reagents. Such determinants may include, for esamples, particular species of collagen and glycoproteins, such as HLA-DR or similar proteins, which have been reported to be present on the surface of atherosclerotic smooth muscle cells.
Detailed DescriptiQn Chemical changes are known to occur in the arterial wall during atherogenesis. Fragmentation of elastin fibers, disruption of endothelial cells, and 5 proliferation of fibroblasts and smooth muscle cells will typically be observed. Increased synthesis of collagen and changes in the distribution of collagen types also occur. New capillary ingrowth and the presence of foam cells with large accumulations of 10 cholesterol are also typical.
During the formation of atherosclerotic lesions, the elastin present in the arterial wall becomes enzymatically degraded. This fragmented elastin is chemically different from native elastin.
15 Additionally, the composition of the proteoglycans which coat the arterial wall changes markedly; the content of other proteoglycans decreases and that of chondroitin sulfate proteoglycan increases. These two chemical changes are esploited in the present 20 invention.
In the preferred embodiments of the invention, antibodies are raised against elastin and chondroitin sulfate proteoglycans (CSPG). These antibodies or fragments derived therefrom are then 25 used to create conjugated diagnostic reagents.
The invention will nest be described in connection with certain non-limiting esamples.
~2~35~23 g Example 1 Antibodies to human elastin were used to image balloon angioplasty-induced lesions in rabbit aorta. The particular antibodies were polyclonal 5 sheep anti-human lung amorphorous elastin antibodies obtained from Dr. J. Rosenbloom of the university of Pennsylvania. Such antibodies can be generated independently by known techniques. For esample, human elastin can be isolated from a lung autopsy 10 specimen, emulsified with Freund's complete adjuvant and then injected subcutaneously at multiple sites into a sheep (e.g., 10 - 20 milligrams). One month later, the animal can be boosted (e.g., with 5 milligrams of the same antigenic preparation), and 15 one week after that, the animal can be bled. The immunoglobulin fraction can be recovered from the whole blood serum by passage through a Protein A-Sepharose affinity chromotography column.
In the present esample, the anti-elastin 20 antibodies were labeled with I-125 (i.e., sodium iodide) as described by McFarlane in Vol. 182, Nature, p. 53 (1958). Excess I-125 can be dialyzed off against physiological saline solution at a pH of about B. The I-125 labeled antibody was then 25 injected intravenously (approsimately 300 millicuries per animal) in each of three rabbits which had four weeks previously undergone balloon diendothelialization of the abdominal aorta.
Twenty-four to forty-eight hours later, the rabbits were sacrificed, the aortas removed, washed with normal saline, cut open lenghtwise, and covered with polyester wrap. The aortas were then carefully 5 placed on a sheet of high speed X-ray film, and the audioradiograph was allowed to develop for four weeks.
The audioradiograph showed clear-cut localization of the elastin on the image at the healing (reendothelization) edge of the aortic 10 lesions produced by the previous trauma. Since this lesion is known to resemble human arteriosclerosis in many important respects, including accumulation of lipoproteins and other pathological changes, the ability of the antiserum to localize at the trauma 15 site and permit the imaging thereof demonstrates the utility of the present invention in imaging vascular disease.
Esample 2 In a second esample, antibodies to human 20 chondroitin sulfate proteoglycan (anti-CSPG) were similarly used to image the abdominal aortas of rabbits which had been previously balloon diendothelialized. The particular antibodies were monoclonal anti-CSPG antibodies obtained from Drs. M.
25 Lark and T. Wight of the University of Washington.
Such antibodies can be generated independently by known technigues. For esample, monoclonal antibodies or active fragments can be obtained by applying ~28~223 generally known cell fusion techniques (cf. G.
Rohler, C. Milstein, Eur. J. Immunol. 6 511-519 (1976) and M. Shulman et al., Nature 276 269-270 (1978)) to obtain a hybridoma producing the anti~ody, 5 by deriving a monoclonal antibody from the hybridoma and (optionally) by subjecting the monoclonal antibody to proteolysis to obtain the active Fab fragment.
Monoclonal antibodies are prepared by 10 obtaining mammalian lymphocytes (preferably spleen cells), committing the lymphocytes to produce antibodies (e.g., by immunizing the mammal with the particular antigenic determinant of interest beforehand~, fusing the lymphocytes with myeloma (or 15 other immortal) cells to form hybrid cells, and then culturing a selected hybrid cell colony in vivo or in vitro to yield antibodies identical in structure and reactivity.
In the particular case of monoclonal 20 antibodies to chondrotin-sulfate proteoglycans (anti-GSPG), such antibodies can be prepared by isolating CSPG from smooth muscle cells in tissue culture. The CSPG can be extracted from the culture medium and purified by ion exchange chromotography.
25 Mice or other animals can be challenged with a solution of the above-derived CSPG in Freund's adjuvant (i.e., 1 - 5 milligram CSPG per milliliter of medium emulsified with one milliliter of adjuvant) injected into the peritoneal cavities of the 30 animals. Si~ weeks later a similar injection (without adjuvant) can be administered as a booster.
12a35~23 Appro~imately ten days later, the mice are killed and their spleens homogenized. The spleen cells are hybridized with mouse myeloma cells by the above-referenced procedure of Kohler and Milstein.
5 The hybridomas so produced are screened to select a cell line producing antibodies which react with human aortic chondroitin sulphate proteoglycan. Large scale antibody production can be obtained from such anti-CSPG producing cell lines by various techniques, 10 including the induction of ascites tumors (i.e., after priming with pristane) and the purification of r such antibodies from the ascites fluid by Protein x~ A-Sepharose~affinity chromotography.
In the present esample, the pure IgM
15 antibody was labeled with I-125 by the same method as described in E~ample 1 and injected into each of three rabbits in a similar manner. Audioradiographs produced as described above clearly showed that the labeled anti-CSPG antibodies imaged the bare, injured 20 areas of the arterial wall and did not image either healthy arterial wall regions or those areas where rapid reendothelialization was occurring. Thus, this antibody can image aspects of vascular disease which are distinct from those detected by the anti-elastin 25 antibodies discussed in E~ample 1.
*
rr~d~
~285~J23 E~ample 3 For comparison, three rabbits were similarly treated with non-specific IgG and three rabbits with non-æpecific IgM. In each case, a similar audioradiograph was made of the animal'æ aorta 48 hours after injection of the I-125 labeled non-specific immunoglobulins. Only a very faint image of the edges of the legions were seen with these antibodies. The images were in no way similar to the images seen with either of the specific antibodies described above.
For a further description of general hybridoma production methods, see Oi and Herzenberg, ~Immunoglobulin-Producing Hybrid Cell Lines~ in S~l~Ç~d Methods in Cellular Immunology (Mishell and Shiiqi, Ed., W.H. Freeman & Co., 1980) and Scearce and Eisenbarth, ~Production of Monoclonal Antibodies...~ in Vol. 103 Methods in Enzymology, pp. 459 - 469 (1983). For descriptions of human hybridoma production techniques, see U.S. Patent No. 4,451,570 issued to Royston et al. on May 29, 1984; U.S. Patent No.
4,529,694 issued to Lazarus et al. on July 16, 1985 and Zurawski et al, ~Continuously Proliferating Human Cell ~ines Synthesizing Antibody of Predetermining Specificity~ in Monoclonal Antibodies (Plenum Press, New York l9tO).
~
.. . ~
~2 R5~d~
Active fragments can be derived from the monoclonal antibodies disclosed herein by a number of techniques. For example, purified monoclonal antibodies can be treated in a buffer ~olution with an enzyme, such as pepsin and subjected to HPLC gel filtration. The appropriate fraction containing Fab can then be collectea and concentrated by membrane filtration or the like. For further description of the general techniques for isolation of active fragments, see for e~ample, Khaw, BA et al., Vol. 23 J. Nucl. Me~ , pp. 1011-1019 ~1982).
The antibodies and fragments used herein can be labeled preferably with radioactive labels, by a variety of techniques other than the above-described McFarland technigue. For e~ample, the biologically active molecules can also be labeled with a radionuclide via conjugation with the cyclic anhydride of diethylenetriamine penta-acetic acid (DTPA) or bromoacetyl aminobenzyl ethylamine diamine tetra-acidic acid (BABE). See generally Hnatowich et al., Vol. 220 Science, pp. 613-315 (1983) and Meares et al. Vol. 142 Analytical Biochemis~y, pp. 68-78 (1984) for further description of labeling techniques.
~'
Backqround The u.S. Government has rights in this invention pursuant to NIH Grant No. ROlHL32975.
The technical field of this invention concerns methods and means for detecting vascular diseases, such as atherosclerotic lesions, and in particular, methods and means employing labeled, target-seeking, biologically active molecules to 10 detect abnormal arterial structures or compositions.
Atherosclerosis is a disease which causes the thickening and hardening of the arteries, particularly the larger artery walls. It is characterized by lesions of raised fibrous plaque 15 which form within the arterial lumen. The p aques are most prevalent in the abdominal aorta, coronary arteries or carotid arteries and they increase progressively with age. They commonly present dome-shaped, opaque, glistening surfaces which bulge 20 into the lumen. A lesion typically will consist of a central core of lipid and necrotic cell debris, capped by a collagen fibromuscular layer.
Complicated lesions will also include calcified deposits and e~hibit various degrees of necrosis, 25 thrombosis and ulceration.
The deformities of the arterial lumen presented by the plaque and associated deposits result in occluded blood flow, and ultimately ischemic heart disease, stroke, or diseases of other 30 organs, if untreated. At present, coronary atherosclerosis is still the leading cause of death in the United States, claiming ths lives of over a half million Americans annually, roughly twice as many as are killed by cancer.
Unfortunately, the early stages of atherosclerosis and related vascular diseases are most often clinically silent. Since lifestyle changes, drug therapy and other means exist for delayinq or reducing vascular occlusion or the 10 stresses on various body organs which result from atherosclerotic lesions, the early detection of atheromatous plaque in the vascular system would be of considerable value in permitting preventive intervention at a time when it can be most effective.
Arteriography, the conventional approach to assessing vascular disease, involves catheterization and the injection of radioopaque substances into the bloodstream in order to image obstructions in the arteries. This procedure involves significant 20 morbidity, in that infection, perforation of the artery, arrhythmia, stroke, infarction and even death can occur. Because of the risks involved, arteriograms typically are reserved for individuals with advanced or acute atherosclerotic disease.
1 A variety of less invasive techniques for the diagnosis of vascular diseases have been proposed. These techniques include plethysmography, thermography and ultrasonic scanning. For a further review of these techniques, see an article by the present inventor and a colleague, Lees and Myers, "Non-Invasive Diagnosis of Arterial Disease", Vol. 27 Annals of Internal Medicine, pp.
475-509 (1982).
Another non-invasive approach to the diagnosis of vascular disease which has been proposed by the present inventor involves the labeling of low density lipoproteins (LDLs) with radioisotopes and the administration of such labeled LDLs to a patient. 8ecause atherosclerotic plaques tend to take up lipoproteins from the blood circulating in the arteries, the labeled LDLs can be imaged with a gamma camera or other radiation detector to provide information on the location and extent of plaque in the vascular system.
For details on this approach, see U.S. Patent No. 4,647,445 entitled "Radiolabelled Lipoproteins and Methods for Making Same" to Robert S. Lees which issued March 3, 1987.
One disadvantage to the use of labeled LDL's is that the patient's own blood typically is the most appropriate source of lipoproteins, and this entails a two or three day delay between the beginning and the end of the study. Often, such a time period is ,::
~ ......
...... .
not available for sick patients. Furthermore, labeled LDLs image acute, rapidly qrowing atherosclerosic lesions, as reported by the present inventor and colleagues, ~ees et al., Journal of Nuclear Mçdi~ag~, Vol. 24, pp. 154-156, 1983.
The need exists to localize less rapidly yrowing artherosclerosic lesions which may not take up LDLs rapidly enough to be imaged. Consequently, there e~ists a need for better non-invasive techniques and reagents capable of detecting vascular diseases, locating arterial lesions and quantifying the e~tent of vascular injury.
;, i28~i223 Summary of the Invention Vascular diseases, including asymptomatic atherosclerosis, can be diagnosed by administering a conjugate diagnostic reagent to a patient and then 5 detecting the location and concentration of the conjugate reagent within the patient's vascular system. The conjugate reagents have a target-seeking, biologically active molecule as one component and a labeling means capable of 10 extracorporeal detection as the other component. The biologically active molecules (BAMs) are chosen to have affinity for structural elements of the arterial wall which are either not present in the normal wall but are found in atherosclerotic lesions, or which 15 are not available to the blood-borne reagent within normal arterial walls, but are e~posed to the reagent in atherosclerotic lesions.
In particular, the invention encompasses conjugates of radionuclides with various antibodies 20 or fragments thereof which have affinity for certain arterial wall components which are exposed to the blood in atherosclerosis. Two conjugated reagents having particularly useful BAMs are disclosed. The BAMs have high affinity for elastin and chondroitin 25 sulfate proteoglycans ~CSPG), respectively. The conjugates of the present invention can be administered individually or in conjunction with each other.
Suitable radionuclides include Co-57, Cu-67, Ga-67, Ga-68, Ru-97, Tc-99m, In-lll, In-113m, I-123, I-125, I-131, Hg-197, Au-198, and Pb-203. The BAMs and radionuclides can be linked by direct labeling 5 (e.g., by acidic buffered reactions or oxidative procedures) or by ligand exchange or chelation. The radionuclides are preferably imaged with a radiation detection means capable of detecting gamma radiation, such as a gamma camera or the like.
Typically, radiation imaging cameras employ a conversion medium (wherein the high energy gamma ray is absorbed, displacing an electron which emits a photon upon its return to the orbital state), photoelectric detectors arranged in a spatial 15 detection chamber (to determine the position of the emitted photons), and circuitry to analyze the photons detected in the chamber and produce an image.
The invention can also be practiced with non-radioactive labeling means, such as magnetic 20 contrast agents capable of detection in magnetic resonance imaging (MRI) systems. In such systems, a strong magnetic field is used to align the nuclear spin vectors of the atoms in a patient's body. The field is then disturbed and an image of the patient 25 is read as the nuclei return to their equilibrium alignments. In the present invention, target-seeking ~AMs can be linked to diamagnetic contrast agents, such as gadolinium, cobalt, nickel, manganese or copper compleses, to form conjugate diagnostic 30 reagents that are imaged extracorporeally with an MRI
system.
~352Z3 The invention will next be described in connection with certain preferred embodiments;
however, it should be clear that various changes, additions and subtractions can be made without 5 departing from the spirit or scope of the invention.
For esample, monoclonal antibodies (or fragments thereof) as well as polyclonal antibodies (or fragments) can be employed as target-seeking, biologically active molecules. Additionally, human 10 antibodies (i.e., obtained from human-human or human-animal hybridomas) can be used as well as animal antibodies.
Moreover, it should be clear that various antigenic determinants can be used to identify 15 atherosclerotic plaque. Although the embodiments that follow describe two such determinants in detail, elastin and chondroitin sulfate proteogylcans (CSPG), it should be clear that other determinants can also be used as targets against which BAMs can be raised 20 and used in conjugate reagents. Such determinants may include, for esamples, particular species of collagen and glycoproteins, such as HLA-DR or similar proteins, which have been reported to be present on the surface of atherosclerotic smooth muscle cells.
Detailed DescriptiQn Chemical changes are known to occur in the arterial wall during atherogenesis. Fragmentation of elastin fibers, disruption of endothelial cells, and 5 proliferation of fibroblasts and smooth muscle cells will typically be observed. Increased synthesis of collagen and changes in the distribution of collagen types also occur. New capillary ingrowth and the presence of foam cells with large accumulations of 10 cholesterol are also typical.
During the formation of atherosclerotic lesions, the elastin present in the arterial wall becomes enzymatically degraded. This fragmented elastin is chemically different from native elastin.
15 Additionally, the composition of the proteoglycans which coat the arterial wall changes markedly; the content of other proteoglycans decreases and that of chondroitin sulfate proteoglycan increases. These two chemical changes are esploited in the present 20 invention.
In the preferred embodiments of the invention, antibodies are raised against elastin and chondroitin sulfate proteoglycans (CSPG). These antibodies or fragments derived therefrom are then 25 used to create conjugated diagnostic reagents.
The invention will nest be described in connection with certain non-limiting esamples.
~2~35~23 g Example 1 Antibodies to human elastin were used to image balloon angioplasty-induced lesions in rabbit aorta. The particular antibodies were polyclonal 5 sheep anti-human lung amorphorous elastin antibodies obtained from Dr. J. Rosenbloom of the university of Pennsylvania. Such antibodies can be generated independently by known techniques. For esample, human elastin can be isolated from a lung autopsy 10 specimen, emulsified with Freund's complete adjuvant and then injected subcutaneously at multiple sites into a sheep (e.g., 10 - 20 milligrams). One month later, the animal can be boosted (e.g., with 5 milligrams of the same antigenic preparation), and 15 one week after that, the animal can be bled. The immunoglobulin fraction can be recovered from the whole blood serum by passage through a Protein A-Sepharose affinity chromotography column.
In the present esample, the anti-elastin 20 antibodies were labeled with I-125 (i.e., sodium iodide) as described by McFarlane in Vol. 182, Nature, p. 53 (1958). Excess I-125 can be dialyzed off against physiological saline solution at a pH of about B. The I-125 labeled antibody was then 25 injected intravenously (approsimately 300 millicuries per animal) in each of three rabbits which had four weeks previously undergone balloon diendothelialization of the abdominal aorta.
Twenty-four to forty-eight hours later, the rabbits were sacrificed, the aortas removed, washed with normal saline, cut open lenghtwise, and covered with polyester wrap. The aortas were then carefully 5 placed on a sheet of high speed X-ray film, and the audioradiograph was allowed to develop for four weeks.
The audioradiograph showed clear-cut localization of the elastin on the image at the healing (reendothelization) edge of the aortic 10 lesions produced by the previous trauma. Since this lesion is known to resemble human arteriosclerosis in many important respects, including accumulation of lipoproteins and other pathological changes, the ability of the antiserum to localize at the trauma 15 site and permit the imaging thereof demonstrates the utility of the present invention in imaging vascular disease.
Esample 2 In a second esample, antibodies to human 20 chondroitin sulfate proteoglycan (anti-CSPG) were similarly used to image the abdominal aortas of rabbits which had been previously balloon diendothelialized. The particular antibodies were monoclonal anti-CSPG antibodies obtained from Drs. M.
25 Lark and T. Wight of the University of Washington.
Such antibodies can be generated independently by known technigues. For esample, monoclonal antibodies or active fragments can be obtained by applying ~28~223 generally known cell fusion techniques (cf. G.
Rohler, C. Milstein, Eur. J. Immunol. 6 511-519 (1976) and M. Shulman et al., Nature 276 269-270 (1978)) to obtain a hybridoma producing the anti~ody, 5 by deriving a monoclonal antibody from the hybridoma and (optionally) by subjecting the monoclonal antibody to proteolysis to obtain the active Fab fragment.
Monoclonal antibodies are prepared by 10 obtaining mammalian lymphocytes (preferably spleen cells), committing the lymphocytes to produce antibodies (e.g., by immunizing the mammal with the particular antigenic determinant of interest beforehand~, fusing the lymphocytes with myeloma (or 15 other immortal) cells to form hybrid cells, and then culturing a selected hybrid cell colony in vivo or in vitro to yield antibodies identical in structure and reactivity.
In the particular case of monoclonal 20 antibodies to chondrotin-sulfate proteoglycans (anti-GSPG), such antibodies can be prepared by isolating CSPG from smooth muscle cells in tissue culture. The CSPG can be extracted from the culture medium and purified by ion exchange chromotography.
25 Mice or other animals can be challenged with a solution of the above-derived CSPG in Freund's adjuvant (i.e., 1 - 5 milligram CSPG per milliliter of medium emulsified with one milliliter of adjuvant) injected into the peritoneal cavities of the 30 animals. Si~ weeks later a similar injection (without adjuvant) can be administered as a booster.
12a35~23 Appro~imately ten days later, the mice are killed and their spleens homogenized. The spleen cells are hybridized with mouse myeloma cells by the above-referenced procedure of Kohler and Milstein.
5 The hybridomas so produced are screened to select a cell line producing antibodies which react with human aortic chondroitin sulphate proteoglycan. Large scale antibody production can be obtained from such anti-CSPG producing cell lines by various techniques, 10 including the induction of ascites tumors (i.e., after priming with pristane) and the purification of r such antibodies from the ascites fluid by Protein x~ A-Sepharose~affinity chromotography.
In the present esample, the pure IgM
15 antibody was labeled with I-125 by the same method as described in E~ample 1 and injected into each of three rabbits in a similar manner. Audioradiographs produced as described above clearly showed that the labeled anti-CSPG antibodies imaged the bare, injured 20 areas of the arterial wall and did not image either healthy arterial wall regions or those areas where rapid reendothelialization was occurring. Thus, this antibody can image aspects of vascular disease which are distinct from those detected by the anti-elastin 25 antibodies discussed in E~ample 1.
*
rr~d~
~285~J23 E~ample 3 For comparison, three rabbits were similarly treated with non-specific IgG and three rabbits with non-æpecific IgM. In each case, a similar audioradiograph was made of the animal'æ aorta 48 hours after injection of the I-125 labeled non-specific immunoglobulins. Only a very faint image of the edges of the legions were seen with these antibodies. The images were in no way similar to the images seen with either of the specific antibodies described above.
For a further description of general hybridoma production methods, see Oi and Herzenberg, ~Immunoglobulin-Producing Hybrid Cell Lines~ in S~l~Ç~d Methods in Cellular Immunology (Mishell and Shiiqi, Ed., W.H. Freeman & Co., 1980) and Scearce and Eisenbarth, ~Production of Monoclonal Antibodies...~ in Vol. 103 Methods in Enzymology, pp. 459 - 469 (1983). For descriptions of human hybridoma production techniques, see U.S. Patent No. 4,451,570 issued to Royston et al. on May 29, 1984; U.S. Patent No.
4,529,694 issued to Lazarus et al. on July 16, 1985 and Zurawski et al, ~Continuously Proliferating Human Cell ~ines Synthesizing Antibody of Predetermining Specificity~ in Monoclonal Antibodies (Plenum Press, New York l9tO).
~
.. . ~
~2 R5~d~
Active fragments can be derived from the monoclonal antibodies disclosed herein by a number of techniques. For example, purified monoclonal antibodies can be treated in a buffer ~olution with an enzyme, such as pepsin and subjected to HPLC gel filtration. The appropriate fraction containing Fab can then be collectea and concentrated by membrane filtration or the like. For further description of the general techniques for isolation of active fragments, see for e~ample, Khaw, BA et al., Vol. 23 J. Nucl. Me~ , pp. 1011-1019 ~1982).
The antibodies and fragments used herein can be labeled preferably with radioactive labels, by a variety of techniques other than the above-described McFarland technigue. For e~ample, the biologically active molecules can also be labeled with a radionuclide via conjugation with the cyclic anhydride of diethylenetriamine penta-acetic acid (DTPA) or bromoacetyl aminobenzyl ethylamine diamine tetra-acidic acid (BABE). See generally Hnatowich et al., Vol. 220 Science, pp. 613-315 (1983) and Meares et al. Vol. 142 Analytical Biochemis~y, pp. 68-78 (1984) for further description of labeling techniques.
~'
Claims (18)
1. A conjugated diagnostic reagent having an antibody or fragment thereof with specific affinity for at least one arterial wall component associated with an abnormality of the vascular system, said arterial component being selected from the group consisting of insoluble, cross-linked elastin and insoluble, cross-linked fragments thereof and chondroitin sulfate proteoglycan compounds, a labeling means for labeling said antibody or fragment thereof, and not including porphyrin or derivatives thereof.
2. The conjugated reagent of claim 1 wherein said antibody or fragment thereof has a specific affinity for insoluble cross-linked elastin and insoluble, cross-linked fragments thereof.
3. The conjugated reagent of claim 1 wherein said antibody or fragment thereof has an affinity for chondroitin sulfate proteoglycan.
4. The conjugated reagent of claim 1 where the labeling means is a radionuclide.
5. The conjugated reagent of claim 4 where the radionuclide is selected from the group of Co-57, Cu-67, Ga-67, Ga-68, Ru-97, Tc-99m, In-111, In-113m, I-123, I-125, I-131, Hg-197, Au-198, and Pb-203.
6. The conjugated reagent of claim 1 wherein the labeling means is a magnetic contrast agent capable of being detected by magnetic resonance imaging techniques.
7. The conjugated reagent of claim 6 wherein the magnetic contrast agent is selected from the group of gadolinium, copper, cobalt, nickel and manganese complexes.
8. The conjugated reagent of claim 1 in which said antibody or fragment thereof is selected from the group consisting of a polyclonal antibody and a monoclonal antibody.
9. The conjugated reagent of claim 8 wherein said fragments are Fab fragments.
10. A method for the detection of diseases of the vascular system including a symptomatic atherosclerosis, the method comprising:
(a) preparing a conjugate of an antibody or fragment thereof having an affinity for at least one arterial wall component being selected from the group consisting of insoluble, cross-linked elastin and insoluble, cross-linked fragments thereof, and chondroitin sulfate proteoglycans, and a labeling means for labeling said antibody or fragment thereof, said conjugate not including porphyrin or derivatives thereof, said labeling means being linked to said antibody or fragment thereof and capable of being detected extracorporeally;
(b) introducing the conjugate into the vascular system via a physiologically compatible vehicle in an amount effective for detection;
(c) detecting the location of the conjugate within the vascular wall with an extracorporeal detection means capable of detecting the labeling means; and (d) quantifying the conjugate concentration at at least one location in order to determine the presence and extent of vascular disease.
(a) preparing a conjugate of an antibody or fragment thereof having an affinity for at least one arterial wall component being selected from the group consisting of insoluble, cross-linked elastin and insoluble, cross-linked fragments thereof, and chondroitin sulfate proteoglycans, and a labeling means for labeling said antibody or fragment thereof, said conjugate not including porphyrin or derivatives thereof, said labeling means being linked to said antibody or fragment thereof and capable of being detected extracorporeally;
(b) introducing the conjugate into the vascular system via a physiologically compatible vehicle in an amount effective for detection;
(c) detecting the location of the conjugate within the vascular wall with an extracorporeal detection means capable of detecting the labeling means; and (d) quantifying the conjugate concentration at at least one location in order to determine the presence and extent of vascular disease.
11. The method of claim 10 wherein the step of preparing a conjugate further includes employing an antibody or fragment thereof having a specific affinity for insoluble, cross-linked elastin and insoluble, cross-linked fragments thereof.
12. The method of claim 10 wherein the step of preparing a conjugate further includes employing an antibody or fragment thereof having an affinity for chondroitin sulfate proteoglycan.
13. The method of claim 10 wherein the step of preparing a conjugate further includes employing a radionuclide selected from the group of Co-57, Cu-67, Ga-67, Ga-68, Ru-97, Tc-99m, In-111, In-113m, I-123, I-125, I-131, H3-197, Au-198 and Pb-203 as the labeling means.
14. The method of claim 10 wherein the step of preparing a conjugate further includes employing a monoclonal antibody or active fragment thereof.
15. The method of claim 10 wherein the step of preparing a conjugate further includes employing a polyclonal antibody or active fragment thereof.
16. The method of claim 10 wherein the step of preparing a conjugate further includes employing a radionuclide as the labeling means and the step of detecting the location of the conjugate within the vascular wall further includes detecting radiation therefrom with a radiation detector.
17. The method of claim 16 wherein the step of detecting radiation further includes employing a gamma camera to detect and make an image of gamma radiation emitted by the labeling means of the conjugate reagent.
18
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US92901286A | 1986-11-10 | 1986-11-10 | |
US929,012 | 1986-11-10 |
Publications (1)
Publication Number | Publication Date |
---|---|
CA1285223C true CA1285223C (en) | 1991-06-25 |
Family
ID=25457176
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA000550932A Expired - Lifetime CA1285223C (en) | 1986-11-10 | 1987-11-03 | Detection of vascular disease |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP0288558A4 (en) |
JP (1) | JPH01501796A (en) |
AU (1) | AU601126B2 (en) |
CA (1) | CA1285223C (en) |
WO (1) | WO1988003413A1 (en) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK408289D0 (en) * | 1989-08-18 | 1989-08-18 | Novo Nordisk As | DIAGNOSTIC REAGENTS |
WO2008075968A1 (en) * | 2006-12-20 | 2008-06-26 | Ge Healthcare As | Contrast agents |
GB201102189D0 (en) * | 2011-02-08 | 2011-03-23 | King S College London | Materials and methods relating to cardiovascular imaging |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4577636A (en) * | 1982-11-23 | 1986-03-25 | The Beth Israel Hospital Association | Method for diagnosis of atherosclerosis |
US4647445A (en) * | 1984-03-28 | 1987-03-03 | Massachusetts Institute Of Technology | Radiolabelled lipoproteins and method for making same |
US4660563A (en) * | 1984-12-31 | 1987-04-28 | Massachusetts Institute Of Technology | Method and means for detection of arterial lesions |
-
1987
- 1987-11-03 CA CA000550932A patent/CA1285223C/en not_active Expired - Lifetime
- 1987-11-09 AU AU83226/87A patent/AU601126B2/en not_active Ceased
- 1987-11-09 WO PCT/US1987/002939 patent/WO1988003413A1/en not_active Application Discontinuation
- 1987-11-09 EP EP19870907892 patent/EP0288558A4/en not_active Withdrawn
- 1987-11-09 JP JP50016987A patent/JPH01501796A/en active Pending
Also Published As
Publication number | Publication date |
---|---|
AU601126B2 (en) | 1990-08-30 |
AU8322687A (en) | 1988-06-01 |
EP0288558A1 (en) | 1988-11-02 |
WO1988003413A1 (en) | 1988-05-19 |
EP0288558A4 (en) | 1990-01-08 |
JPH01501796A (en) | 1989-06-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US4877599A (en) | Detection of vascular disease with labelled antibodies | |
Rubin et al. | 111In-labeled nonspecific immunoglobulin scanning in the detection of focal infection | |
US5026537A (en) | Methods for imaging atherosclerotic plaque | |
CA1338706C (en) | Monoclonal anti-human breast cancer antibodies suitable for imaging breast cancer | |
US6375925B1 (en) | Methods and reagents for non-invasive imaging of atherosclerotic plaque | |
Rainsbury | The localization of human breast carcinomas by radiolabelled monoclonal antibodies | |
CA1252714A (en) | Diagnostic agent for heart disease and use thereof | |
AU628357B2 (en) | Synthetic peptides for arterial imaging | |
Wilbanks et al. | Localization of mammary tumors in vivo with 131i‐labeled fab fragments of antibodies against mouse mammary epithelial (mme) antigens | |
Gratz et al. | Intraindividual comparison of 99m Tc-labelled anti-SSEA-1 antigranulocyte antibody and 99m Tc-HMPAO labelled white blood cells for the imaging of infection | |
CA1285223C (en) | Detection of vascular disease | |
JP2829755B2 (en) | Anti-human myocardial C protein monoclonal antibody and hybridoma producing the antibody | |
WO1998021581A1 (en) | Methods and reagents for non-invasive imaging of atherosclerotic plaque | |
Haisma et al. | Human IgM monoclonal antibody 16.88: pharmacokinetics and immunogenicity in colorectal cancer patients | |
US5250297A (en) | Tumor-associated antigen, antibodies, compositions and uses therefor | |
Babich et al. | Targeted imaging of infection | |
WO1983001004A1 (en) | Specific mammary gland labelling | |
US5840272A (en) | Imaging infectious foci with human IgM 16.88 | |
Chen et al. | Localization of monoclonal antibody TNT‐1 in experimental kidney infarction of the mouse | |
Taylor Jr et al. | Radioimmunodetection of Human Melanoma With Indium-111-labeled Monoclonal Antibodies ¹ | |
Stya et al. | Radioimmunoimaging of human small cell lung carcinoma xenografts in nude mice receiving several monoclonal antibodies | |
EP0424107A1 (en) | A novel tumor-associated antigen | |
JPH01197445A (en) | Diagnosticum for mammary cancer | |
Perkins et al. | Immunoscintigraphy and immunotherapy 1988 Report of the 3rd IRIST Meeting, Frankfurt/Main, March 1988 | |
EP0898970A1 (en) | Diagnostic agent for digestive diseases |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MKLA | Lapsed |